A Multicenter, Double-Blind, Placedbo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG0002) on reducing Infarct volume in Acute Ischemic Stroke.

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2013 - May 31, 2015